2024年5月22日，怡和嘉业公告分红方案，每10股派息(税前)10元，转增4股，除权除息日为2024年5月 29日。 怡和嘉业募集资金总额为191,808.00万元，募集资金净额为173,826.74万元。怡和嘉业实际募资净额比原 拟募资多100,026.98万元。怡和嘉业2022年10月25日披露的招股书显示，公司原拟募集资金73,799.76万 元，拟用于"年产30万台呼吸机及350万套配件"、"营销网络及品牌建设项目"、"医疗设备研发中心项 目"、"补充流动资金"。 怡和嘉业的保荐机构(主承销商)是中金公司（601995），保荐代表人是陈婷婷、谢显明。怡和嘉业发行 费用共计18,302.02万元，其中保荐及承销费用15,715.82万元。 中国经济网北京6月18日讯瑞迈特（301367）(301367.SZ)今日收报79.36元，跌幅2.17%。目前该股股价 低于发行价。 怡和嘉业于2022年11月1日在深交所创业板上市，公开发行新股1,600万股，占发行后总股本的25%，发 行价格为119.88元/股。 怡和嘉业2025年5月21日发布关于变更公司名称、证券简称暨完成工商变更登记的公告。北京怡和嘉业 ...

Core Viewpoint - The medical device industry experienced a slight decline of 0.04% as of the market close on June 11, with a net outflow of approximately 238.92 million in capital [1] Group 1: Market Performance - A total of 47 stocks in the sector increased in value, while 70 stocks saw a decline [1] - The top-performing stocks included: - Haorunbo (4.39%) - AoJing Medical (4.36%) - Sanor Bio (4.27%) - Tianzhihang-U (3.22%) - Huitai Medical (3.0%) [1][1] Group 2: Notable Declines - The stocks with the largest declines included: - Chenguang Medical (-2.8%) - Guanhao Biological (-2.72%) - Chunli Medical (-2.44%) - Kaili Medical (-2.12%) - Ruimaite (-1.76%) [1][1][1] - Notable net capital outflows were observed in: - Chenguang Medical (-25.14 million) - Guanhao Biological (-38.67 million) - Chunli Medical (-5.48 million) [1][1]

转自：中国质量报 本报讯 （记者丁 莹）日前，天津怡和嘉业医疗科技有限公司（以下简称"怡和嘉业"）牵头的"无创呼吸 系统关键技术研发与临床应用"项目获天津市科技进步奖一等奖。 无创呼吸机是目前治疗呼吸系统疾病最有效的医疗器械。发达国家技术成熟早，但对我国存在技术壁 垒。本次获奖项目"无创呼吸系统关键技术研发与临床应用"在核心技术、关键设备、系统平台、国际标 准等方面均取得突破，拥有完全自主知识产权。首都医科大学附属北京朝阳医院作为牵头单位，联合国 内30家医院协作完成"高强度与低强度无创正压通气对慢性阻塞性肺疾病急性加重患者气管插管需求影 响的多中心随机对照研究"，基于上述项目成果（家用呼吸机、呼吸数据管理云）于2024年在国际顶级 医学期刊美国医学会杂志上发表论文。 中国工程院院士、航空医学和生物医学工程专家俞梦孙评价说，这项研究突破了制约我国无创呼吸机发 展的关键核心技术，对我国无创通气治疗的装备革新具有重要意义。 该项目组还在呼吸慢病管理系统上取得突破，基于超30万个无创呼吸治疗活跃用户的呼吸相关数据打造 了呼吸数据管理云平台，打通医院、家庭两个使用场景。患者及其家人可以对睡眠呼吸数据进行实时查 看；医 ...

Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2][3]. - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - Ruimait is a leading domestic company in home non-invasive ventilators and masks, with products sold in over 100 countries and regions, holding multiple certifications including NMPA, FDA, and CE [2][3]. Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents. It also has 202 valid overseas patents [3]. Market Position - Ruimait's home non-invasive ventilators hold a 30.6% market share in China, ranking first, and a 12.4% share globally, ranking second in the industry [4][5]. Brand Strategy - The rebranding to "Ruimait" signifies a strategic alignment between product identity and capital market perception, enhancing brand value and market penetration [4][5]. - The name "Ruimait" combines "respiratory" and "smart," reflecting the company's commitment to respiratory health and innovative technology [5]. Product Development - The launch of the Ruimait oxygen bottle marks the company's entry into the consumer goods market, featuring a unique mechanical valve design that enhances oxygen utilization [6]. - The collaboration with Shenzhen Hanyu Pharmaceutical Co., Ltd. aims to develop new products for health consumer channels, targeting mild sleep disorder populations [6][7]. Market Expansion - The company is enhancing its domestic channel strategies and has seen improvements in revenue and gross margin in the first quarter [7][8]. - In Europe, the company has established a cloud platform and onboarded over 20 agents, laying the groundwork for future growth in the mainstream medical insurance market [8].

Core Viewpoint - The company has shown a recovery in performance with Q1 2025 results exceeding expectations, driven by improved order fulfillment in the U.S. market and ongoing domestic growth initiatives [1][3][10] Financial Performance - For 2024, the company reported revenue of 843 million yuan (down 24.85%), net profit attributable to shareholders of 155 million yuan (down 47.74%), and net profit excluding non-recurring items of 92 million yuan (down 61.79%) [2][3] - In Q1 2025, revenue reached 265 million yuan (up 38.11%), net profit attributable to shareholders was 72 million yuan (up 44.11%), and net profit excluding non-recurring items was 60 million yuan (up 43.18%) [2][4] Market Outlook - The company anticipates continued growth in Q2 2025, particularly in the U.S. market, as the low base effect from the previous year supports performance [1][5] - The company plans to enhance brand promotion and channel development in both domestic and international markets throughout the year [1][5][10] Business Segmentation - Revenue from home respiratory therapy products in 2024 was 527 million yuan (down 38.15%), while consumables revenue was 284 million yuan (up 46.22%) [4] - In Q1 2025, home respiratory therapy revenue was 176 million yuan (up 62.80%), and consumables revenue was 81 million yuan (up 7.46%) [4][9] Brand Development - The company changed its name from "怡和嘉业" to "瑞迈特" on May 21, aiming to enhance brand influence and align its corporate identity with its core product offerings [2][5][6] R&D and Innovation - The company is committed to maintaining high levels of R&D investment to improve product performance and expand market share [1][5][10] - Future innovations in respiratory products are expected to leverage AI and brain-machine interface technologies for enhanced functionality [6] Incentive Plans - The company announced a stock incentive plan for 2025, aiming to grant up to 704,000 restricted shares to 54 key personnel, with performance targets set for revenue growth [7]

证券代码：301367 证券简称：瑞迈特 北京瑞迈特医疗科技股份有限公司 投资者关系活动记录表 编号：2025—007 | | □特定对象调研 □ 分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | 类别 | □ 新闻发布会 √路演活动 | | | | | □现场参观 | | | | | □其他 | | | | 参与单位名称 | 详见附件清单 | | | | 时间 | 2025 年 5 月 22 日-2025 年 月 23 日 | 5 | | | 地点 | 深圳、北京 | | | | 上市公司接待人 | 副总经理兼董事会秘书：杜祎程 | | | | 员姓名 | 证券事务代表：刘士岩 | | | | | 一、公司简要介绍 | | | | | 公司 2001 年成立，2003 年第一台多导睡眠监测仪上市，2007 | | | | | 年第一台 CPAP 睡眠呼吸机上市，2008 年通过 CE 认证，2012 | | 年 | | | 通过美国 认证，2016 年 新品牌成立，同年呼吸数据管 FDA BMC | | | | | ...

重要的消息有哪些 潘功胜主持召开金融支持实体经济座谈会 5月19日，中国人民银行行长潘功胜主持召开金融支持实体经济座谈会并讲话。金融监管总局副局长周亮出席会议并讲话。中国人民银行副行长宣昌能、邹 澜出席会议。 会议强调，要实施好适度宽松的货币政策，满足实体经济有效融资需求，保持金融总量合理增长。加力支持科技创新、提振消费、民营小微、稳定外贸等重 点领域，用好用足存量和增量政策，提高金融支持实体经济质效，支持经济结构调整、转型升级和新旧动能转换。强化货币政策执行和传导，维护市场竞争 公平秩序，推动金融服务实体经济和银行自身可持续发展的有机统一。有序推进人民币国际使用，提高贸易和投融资便利化水平。统筹发展和安全，坚决维 护国家金融安全。 前4个月公共财政收入累计降幅继续收窄 中央收入月度增幅由负转正 财政部公布2025年1—4月财政收支情况，印花税1614亿元，同比增长18.9%。其中，证券交易印花税535亿元，同比增长57.8%。 国家能源局：4月份全社会用电量7721亿千瓦时，同比增长4.7% 国家能源局5月20日发布4月份全社会用电量等数据。4月份，全社会用电量7721亿千瓦时，同比增长4.7%。1—4月， ...

Key Points - China Shipbuilding Industry Corporation plans to achieve operating revenue exceeding 60 billion yuan by 2025, with a record high backlog of orders exceeding 1.4 billion yuan and over 30 million deadweight tons of civil ship orders [2] - The company has a production schedule extending to the end of 2028, with 90% of new orders being bulk orders for main ship types and nearly 60% of civil ship orders being green ship types [2] IPO Issuance Dynamics - Chao Hong Ji is planning to issue H-shares on the Hong Kong Stock Exchange, with details yet to be determined, while its operational status remains normal [4] - Zhaoyi Innovation intends to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [5] Refinancing Dynamics - Jiu Hua Tourism plans to issue A-shares to specific investors, raising up to 500 million yuan for various projects, including upgrades to hotel facilities and transportation equipment [7] - Yue Gui Co. intends to raise up to 900 million yuan through a private placement of A-shares for several development projects [8] Regulatory Compliance Dynamics - Star Technology received a regulatory letter from the Shenzhen Stock Exchange for inaccurate revenue recognition in its financial reports, affecting reported revenues by 12 million yuan and 170 million yuan for the half-year and third-quarter reports, respectively [10] - ST Huaxi's controlling shareholder has been detained and is under investigation, but the company's operations remain normal [11] Company Announcements - Jie Hua Te plans to acquire a 40.89% stake in Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [14] - Zhongjin Environment has changed its name to "Nanfang Pump Industry," aligning its name with its main business [15] - Yi He Jia Ye has changed its name to "Rui Mai Te," reflecting its business and development strategy [16] - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Resources, which will become a subsidiary [17] - Weiling Co. successfully acquired a 74.3% stake in Jiayu Mining for 220 million yuan, expanding its presence in the non-ferrous metal resources sector [18] - Yuanxing Energy has changed its name to "Bohua Chemical," aligning its name with its main business [19] - Gansu Energy reported a safety incident at its Wangjiashan coal mine, resulting in three fatalities, but overall operations remain unaffected [20] - Huili B's stock may be delisted due to a market capitalization below 300 million yuan [21] - Kangda New Materials plans to sell a 51% stake in Chengdu Biko Technology for 188 million yuan, constituting a related party transaction [22] - Andeli has terminated its plan to issue A-shares due to the disqualification of its securities service provider [23]

重要的消息有哪些 潘功胜主持召开金融支持实体经济座谈会 5月19日，中国人民银行行长潘功胜主持召开金融支持实体经济座谈会并讲话。金融监管总局副局长周 亮出席会议并讲话。中国人民银行副行长宣昌能、邹澜出席会议。 会议强调，要实施好适度宽松的货币政策，满足实体经济有效融资需求，保持金融总量合理增长。加力 支持科技创新、提振消费、民营小微、稳定外贸等重点领域，用好用足存量和增量政策，提高金融支持 实体经济质效，支持经济结构调整、转型升级和新旧动能转换。强化货币政策执行和传导，维护市场竞 争公平秩序，推动金融服务实体经济和银行自身可持续发展的有机统一。有序推进人民币国际使用，提 高贸易和投融资便利化水平。统筹发展和安全，坚决维护国家金融安全。 前4个月公共财政收入累计降幅继续收窄 中央收入月度增幅由负转正 财政部5月20日公布的数据显示，1—4月全国一般公共预算收入80616亿元，同比下降0.4%，降幅比一 季度收窄0.7个百分点。分中央和地方看，中央一般公共预算收入下降3.8%，降幅比一季度收窄1.9个百 分点，其中4月中央收入增长1.6%，今年以来首月实现正增长；地方一般公共预算收入增长2.2%，增幅 与一季度持 ...